Evidence map›Paper›PMID 26428661›Full record

ReviewJournal of gastroenterology2016

Gastric cancer stem cells: evidence, potential markers, and clinical implications.

Daniel Brungs, Morteza Aghmesheh, Kara L Vine, Therese M Becker, Martin G Carolan, Marie Ranson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. FTO-mediated mJournal of cancer research and clinical oncology · 2023
    Article
  15. Article
  16. Review
  17. Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Article
  18. Article
  19. Review
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel BrungsIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, 2522, Australia. daniel.brungs@sesiahs.health.nsw.gov.au.
Morteza AghmeshehIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, 2522, Australia.
Kara L VineIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, 2522, Australia.
Therese M BeckerCONCERT-Translational Cancer Research Centre, Sydney, New South Wales, Australia.
Martin G CarolanIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, 2522, Australia.
Marie RansonIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, 2522, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is a significant global health problem. It is the fifth most common cancer and third leading cause of cancer-related death worldwide (Torre et al. in CA Cancer J Clin 65(2):87-108, 2015). Despite advances in treatment, overall prognosis remains poor, due to tumour relapse and metastasis. There is an urgent need for novel therapeutic approaches to improve clinical outcomes in gastric cancer. The cancer stem cell (CSC) model has been proposed to explain the high rate of relapse and subsequent resistance of cancer to current systemic treatments (Vermeulen et al. in Lancet Oncol 13(2):e83-e89, 2012). CSCs have been identified in many solid malignancies, including gastric cancer, and have significant clinical implications, as targeting the CSC population may be essential in preventing the recurrence and spread of a tumour (Dewi et al. in J Gastroenterol 46(10):1145-1157, 2011). This review seeks to summarise the current evidence for CSC in gastric cancer, with an emphasis on candidate CSC markers, clinical implications, and potential therapeutic approaches.

Indexed as

Biomarkers, TumorGlobal HealthHumansNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplastic Stem CellsPrognosisStomach NeoplasmsBiomarkers, TumorALDH1Cancer stem cellsCD133CD44CD44vGastric cancerStomach neoplasms

Identifiers

PMID26428661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.